Crispr Therapeutics AG (NASDAQ:CRSP) – Equities researchers at Oppenheimer issued their Q2 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a research note issued to investors on Tuesday, November 12th. Oppenheimer analyst S. Tuerkcan forecasts that the company will earn ($0.95) per share for the quarter. Oppenheimer has a “Outperform” rating and a $65.00 price target on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q3 2020 earnings at ($1.29) EPS and Q4 2020 earnings at ($1.38) EPS.
CRSP has been the subject of a number of other research reports. Chardan Capital set a $72.50 price target on Crispr Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 21st. Canaccord Genuity assumed coverage on Crispr Therapeutics in a research report on Friday, July 26th. They issued a “buy” rating and a $72.00 price target for the company. Roth Capital upped their price target on Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, BTIG Research upped their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the stock a “positive” rating in a research report on Tuesday, July 30th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $57.95.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 21.40% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NEXT Financial Group Inc boosted its stake in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 549 shares during the last quarter. Benjamin Edwards Inc. boosted its stake in Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. bought a new position in Crispr Therapeutics during the third quarter valued at approximately $26,000. US Bancorp DE boosted its stake in Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the last quarter. Finally, BSW Wealth Partners bought a new position in Crispr Therapeutics during the second quarter valued at approximately $39,000. 51.09% of the stock is owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: How to identify percentage decliners
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.